GlycoMimetics gains on updated AML data at ASH

GlycoMimetics jumped $2.13 (15%) to $16.45 on Tuesday after reporting updated data at the American Society of Hematology meeting from a Phase I/II trial of

Read the full 259 word article

User Sign In